The pharmacological profile of TX 066 (17 alpha-acetoxy-6-methyl-19-nor-4,6-pregna-diene-3,20-dione), a new oral progestative.
17 alpha-Acetoxy-6-methyl-19-nor-4,6-pregna-diene-3,20-dione (TX 066) has the pharmacological profile of a pure progestogen with no side effect such as androgenic activity. Its pituitary suppressing effect is relatively weak, as is also its antiestrogenic activity. It possesses a powerful antiandrogenic effect, which, in addition to the classic uses for progestogens, may make TX 066 useful in the treatment of certain diseases such as prostatic hypertrophy or the Stein-Leventhal syndrome.
D000311:Adrenal Glands / Q000187:drug effects; D000726:Androgen Antagonists; D000728:Androgens; D000818:Animals; D000893:Anti-Inflammatory Agents; D004967:Estrogens / Q000096:biosynthesis; D005260:Female; D005333:Fetus / Q000187:drug effects; D006062:Gonadotropins / Q000037:antagonists & inhibitors; D008535:Megestrol; D051379:Mice; D009649:Norpregnadienes / Q000494:pharmacology*; D010060:Ovulation / Q000187:drug effects; D011247:Pregnancy; D045167:Progesterone Congeners / Q000494:pharmacology*; D051381:Rats; D013997:Time Factors; D014882:Water-Electrolyte Balance / Q000187:drug effects
D000726:Androgen Antagonists; D000728:Androgens; D000893:Anti-Inflammatory Agents; D004967:Estrogens; D006062:Gonadotropins; D009649:Norpregnadienes; D045167:Progesterone Congeners; C038501:nomegestrol acetate; D008535:Megestrol